RADIOIODINE TREATMENT OF HYPERTHYROIDISM IN THE ELDERLY

P1030

Teresa Azevedo¹, Teresa Martins¹, João Neto², Sofia Oliveira², Eugénia Rovira², Fernando Rodrigues¹



¹Department of Endocrinology, ²Department of Nuclear Medicine. Portuguese Institute of Oncology (IPO), Coimbra, Portugal.


BACKGROUND AND AIMS

- Treatment of hyperthyroidism in older adults is crucial to reduce its morbidity and mortality.
- Radioactive iodine has been widely used in this age group due to its efficacy, safety and cost-effectiveness.
- The aim of this study was to determine the efficacy of ¹³¹I for treatment of hyperthyroidism in the elderly.

METHODS

- Retrospective study of 86 hyperthyroid patients aged ≥ 65 years who performed radioiodine therapy for benign thyroid disease.
- We excluded 22 patients who did not have a minimal follow-up of 1 year.
- We evaluated the following parameters: gender, age, thyroid disease, clinical and laboratory situation at 1, 3 and 5 years after treatment.
- Dose of 131 lodine = [specific activity (μ Ci/g) x glandular volume (g)] / % 131 l fixation at 24 h

RESULTS



DISCUSSION

- The majority of patients (87.6%) needed only one dose of radioiodine.
- During the follow-up there was:
 - Increase of hypothyroid patietns: 10%, 24% and 38% at 1, 3 and 5 years after radioiodine therapy, respectively;
 - Reduction of hyperthyroid patients: 27%, 12% and 6% at 1, 3 and 5 years after radioiodine therapy, respectively;
 - Maintenance of euthyroid patients: 63%, 45% and 56% at 1, 3 and 5 years after radioiodine therapy, respectively.
- There were no statistically significant differences between administered doses of 131 in cases of resolved hyperthyroidism versus the others.

CONCLUSIONS

- Radioiodine therapy proved to be effective and safe to control hyperthyroidism in this age group.
- The cell necrosis induced by radioiodine occurs gradually hence its effect may not be achieved immediately.